News
NICE publishes final guidance backing Jyseleca for rheumatoid arthritis
The National Institute for Health and Care Excellence (NICE) has published its final appraisal determination (FAD) recommending the use of Gilead Sciences and Galapagos’ Jyseleca (filgotinib) for the treatment of rheumatoid arthritis (RA).